The company is expected to report strong numbers in the second quarter, led by growth across all segments. Revenues are likely to rise up to 14% year-on-year, and profit for the quarter is seen jumping 54% year-on-year, according to Kotak Equities.
“We bake in 13% YoY sales growth in the hospitals segment in 2QFY25, led by volume pick-up and better occupancies. We expect ARPOB growth to remain moderated due to higher secondary procedures,” the brokerage said.
HealthCo sales are likely to grow 15% YoY, driven by growth in pharmacy distribution sales on account of the store expansion as well as traction in 24/7.
EBITDA for the September quarter is seen rising 14% YoY to Rs 720 crore due to higher volumes, growth in specialty segment in Apollo Health, and reduced opex in Apollo 24/7.
EBITDA margin may improve by 63 bps QoQ to 24.2%, but decline 71 bps YoY impacted by higher clinical talent and marketing cost. Offline pharmacy will likely continue its high YoY growth of 17-18%.”With enhanced footfalls in primary care, lower customer acquisition costs, and focus on omni-channel, Apollo Health is expected to register 7.8% YoY revenue growth and 40% YoY EBITDA growth,” Motilal Oswal said.In the preceding June quarter, the company reported 83% growth in its consolidated net profit at Rs 305 crore and revenue from operations in the reporting period increased 15% year-on-year to Rs 5,086 crore.
Investors will closely monitor GMV outlook in Apollo 24/7 and also look for updates on capacity expansion at Gurugram, Hyderabad,
Kolkata, Pune and Mysore.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Source link
